selected scholarly activity
-
academic article
- Lung cancer chemotherapy agents increase procoagulant activity via protein disulfide isomerase-dependent tissue factor decryption. Blood Coagulation and Fibrinolysis: international journal in haemostasis and thrombosis. 26:36-45. 2015
- Survival of Patients with Non-Small-Cell Lung Cancer after a Diagnosis of Brain Metastases. Current Oncology. 20:300-306. 2013
- Funding Oncology Clinical Trials: Are Cooperative Group Trials Sustainable?. Journal of Clinical Oncology. 30:1456-1461. 2012
- A qualitative study evaluating causality attribution for serious adverse events during early phase oncology clinical trials. Investigational New Drugs. 29:1013-1020. 2011
- A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada—Clinical Trials Group Trial, MA.12). Annals of Oncology. 21:283-290. 2010
- Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study. Journal of Clinical Oncology. 28:49-55. 2010
- Anticoagulation and Bleeding: A Pooled Analysis of Lung Cancer Trials of the NCIC Clinical Trials Group. Journal of Thoracic Oncology. 4:586-594. 2009
- Tumor Cavitation: Impact on Objective Response Evaluation in Trials of Angiogenesis Inhibitors in Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 27:404-410. 2009
- Phase I and Pharmacokinetic Study of Daily Oral AZD2171, an Inhibitor of Vascular Endothelial Growth Factor Tyrosine Kinases, in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non–Small-Cell Lung Cancer: The National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology. 26:1871-1878. 2008
- Phase II Study of Vandetanib or Placebo in Small-Cell Lung Cancer Patients After Complete or Partial Response to Induction Chemotherapy With or Without Radiation Therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. Journal of Clinical Oncology. 25:4278-4284. 2007
- Absence of Stabilizing Mutations of β-Catenin Encoded by CTNNB1 Exon 3 in a Large Series of Sporadic Parathyroid Adenomas. Journal of Clinical Endocrinology and Metabolism. 92:1564-1566. 2007
- Randomized Phase III Study of Matrix Metalloproteinase Inhibitor BMS-275291 in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. Journal of Clinical Oncology. 23:2831-2839. 2005
- Effects of Long-term Vitamin E Supplementation on Cardiovascular Events and Cancer. JAMA: Journal of the American Medical Association. 293:1338-1338. 2005
- Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer. Lung Cancer. 46:361-368. 2004
- Safety of Treatment of Metastatic Breast Cancer With Trastuzumab Beyond Disease Progression. Journal of Clinical Oncology. 22:1063-1070. 2004
- Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel. Journal of Clinical Oncology. 21:3965-3971. 2003
- Quality of Life in a Randomized Trial of Group Psychosocial Support in Metastatic Breast Cancer: Overall Effects of the Intervention and an Exploration of Missing Data. Journal of Clinical Oncology. 21:1944-1951. 2003
- Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma. Cancer. 92:595-600. 2001
- A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours. Annals of Oncology. 11:1579-1584. 2000
- Lessons learned from enrollment in the BEST study—A multicenter, randomized trial of group psychosocial support in metastatic breast cancer. Journal of Clinical Epidemiology. 53:47-55. 2000
- Phase II Trial of N,N-Diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl and Doxorubicin Chemotherapy in Metastatic Breast Cancer: A National Cancer Institute of Canada Clinical Trials Group Study. Journal of Clinical Oncology. 17:3431-3437. 1999
- Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. Journal of Clinical Oncology. 16:2651-2658. 1998
- Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.. Journal of Clinical Oncology. 16:2651-2658. 1998
- A phase I trial of high-dose paclitaxel, cyclophosphamide and mitoxantrone with autologous blood stem cell support for the treatment of metastatic breast cancer. European Journal of Cancer. 34:1008-1014. 1998
- The supportive care needs of newly diagnosed cancer patients attending a regional cancer center. Cancer. 80:1518-1524. 1997
- Moving promising research findings to the clinic: Methodological issues in the design and conduct of clinical trials of retinoids. International Journal of Cancer. 70:467-469. 1997
- Randomized trial of group psychosocial support in metastatic breast cancer: the BEST study. Cancer Treatment Reviews. 22:91-96. 1996
- The arotinoids: early clinical experience and discussion of future development.. Leukemia. 8:1817-1824. 1994
- Combination 13-cis-retinoic acid and interferon alpha-2a in the therapy of solid tumors.. Leukemia. 8:1622-1625. 1994
- Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. The Lancet. 343:886-889. 1994
- Phase II Trial of 13-cis-Retinoic Acid Plus Interferon in Non-Small-Cell Lung Cancer: For the National Cancer Instit ute of Canada Clinical Trials Group. Journal of the National Cancer Institute. 86:306-309. 1994
- Combination 13-cis-retinoic acid and interferon alpha-2a in the therapy of solid tumors.. Leukemia. 8 Suppl 3:S38-S41. 1994
- Patterns of failure following loco-regional radiotherapy in the treatment of limited stage small cell lung cancer. International Journal of Radiation: Oncology - Biology - Physics. 28:355-362. 1994
- The arotinoids: early clinical experience and discussion of future development.. Leukemia. 8 Suppl 3:S42-S49. 1994
- Tamoxifen and cancer of the endometrium.. CMAJ. 148:2113-2114. 1993
- Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group.. Journal of Clinical Oncology. 11:336-344. 1993
- A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer. European Journal of Cancer. 29:37-43. 1993
- Chemotherapy induced amenorrhoea in a randomised trial of adjuvant chemotherapy duration in breast cancer. European Journal of Cancer. 29:21-23. 1993
- The Canadian Experience with Intensive Fluorouracil, Epirubicin and Cyclophosphamide in Patients with Early Stage Breast Cancer. Drugs. 45:51-59. 1993
- The effect of systemic adjuvant chemotherapy on local breast recurrence in node positive breast cancer patients treated by lumpectomy without radiation. British Journal of Cancer. 65:130-132. 1992
- Toxic megacolon associated with anticancer chemotherapy.. Canadian Journal of Surgery. 34:339-341. 1991
- A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer.. Journal of Clinical Oncology. 8:1217-1225. 1990
- Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer a phase I/II study. Cancer. 65:1895-1902. 1990
- Recruitment for an efficacy study in chemoprevention—The concerned smoker study. Preventive Medicine. 18:700-710. 1989
- Etretinate Blood Levels in Monitoring of Compliance and Contamination in a Chemoprevention Trial. Journal of the National Cancer Institute. 81:795-798. 1989
- Quality of life in stage II breast cancer: an instrument for clinical trials.. Journal of Clinical Oncology. 6:1798-1810. 1988
- The Thrombogenic Effect of Anticancer Drug Therapy in Women with Stage II Breast Cancer. New England Journal of Medicine. 318:404-407. 1988
- Chemotherapy of advanced ovarian carcinoma: Initial experience using a platinum-based combination. Cancer. 49:1778-1783. 1982
-
conference paper
- Lung cancer chemotherapy agents induce protein disulphide isomerase dependent tissue factor decryption resulting in increased procoagulant activity in vitro and in vivo. Journal of Thrombosis and Haemostasis. 378-379. 2013
- A randomized double-blind trial of carboplatin plus paclitaxel (CP) with daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo (PLA) in patients (pts) with previously untreated advanced non-small cell lung cancer (NSCLC): NCIC Clinical Trials Group study BR29. Journal of Clinical Oncology. 2012
- Lung Cancer Chemotherapy Agents Increase Procoagulant Activity In Vitro and In Vivo. Blood. 19-20. 2011
- Funding academic oncology clinical trials.. Journal of Clinical Oncology. e16507-e16507. 2011
- Overall survival [OS] results of NCIC Clinical Trials Group [CTG] BR.24: a randomized, double-blind trial of carboplatin plus paclitaxel [C plus P] with either daily oral cediranib, a potent inhibitor of all vascular endothelial growth factor receptor tyrosine kinases, or placebo, in advanced non-small cell lung cancer [NSCLC]. Journal of Thoracic Oncology. S353-S353. 2009
- Priority health needs for patients receiving concurrent chemotherapy and radiation for stage III non-small cell lung cancer and impact of the role of the advanced practice nurse (APN). Journal of Thoracic Oncology. S436-S437. 2009
- Quality of life (QOL) outcomes with cediranib/placebo in combination with carboplatin/paclitaxel (CP) in advanced non-small cell lung cancer (ANSCLC): results from NCIC CTG BR.24. Journal of Thoracic Oncology. S288-S288. 2009
- Survival of patients with non small cell lung cancer (NSCLC) following diagnosis of brain metastases. Journal of Thoracic Oncology. S543-S544. 2009
- Treatment and outcome of patients with brain metastases from non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2009
- RANDOMIZED, DOUBLE-BLIND PHASE II TRIAL OF CARBOPLATIN plus PACLITAXEL [C plus P] WITH EITHER DAILY ORAL CEDIRANIB, AN INHIBITOR OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR [VEGFR] TYROSINE KINASES, OR PLACEBO, IN ADVANCED NON-SMALL CELL LUNG CANCER [NSCLC]: A STUDY OF THE NATIONAL CANCER INSTITUTE OF CANADA CLINICAL TRIALS GROUP. Annals of Oncology. 90-91. 2008
- Anticoagulation and bleeding: A pooled analysis of lung cancer trials of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology. 8065-8065. 2008
- Causality assessment of adverse events in oncology clinical trials: A qualitative study. Pharmacoepidemiology and Drug Safety. S181-S181. 2007
- Development and validation of an adverse event causality assessment tool for use in oncology clinical trials. Pharmacoepidemiology and Drug Safety. S180-S181. 2007
- PD3-2-7: Implications of tumour cavitation on response assessment in trials of Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors in combination with platinum-based chemotherapy for advanced non-small cell lung cancer (NSCLC): An analysis of trials conducted by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG).. Journal of Thoracic Oncology. S465-S465. 2007
- Delays in diagnosis and initiating treatment for patients with lung cancer.. Journal of Clinical Oncology. 326S-326S. 2006
- P-936 Use of an algorithm to aid determination of causality in early clinical trials of lung cancer using targeted therapy. Lung Cancer. S365-S365. 2005
- The effect of doxycycline on bone turnover and tumor markers in breast cancer (BC) patients with skeletal metastases.. Journal of Clinical Oncology. 240S-240S. 2005
- The BEST study - A Canadian multicenter randomized trial of group psychosocial support in metastatic breast cancer. Early results.. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer. S43-S43. 2000
- Offering a choice between two adjuvant chemotherapy regimens: a pilot study to develop a decision aid for women with breast cancer. Patient Education and Counseling. 283-291. 1999
- A DOUBLE-BLIND RANDOMIZED TRIAL OF MINI-DOSE WARFARIN FOR THE PREVENTION OF THROMBOEMBOLISM (TE) IN PATIENTS WITH STAGE-IV BREAST-CANCER. Thrombosis and Haemostasis. 981-981. 1993
- A RANDOMIZED TRIAL COMPARING 12 WEEKS WITH 36 WEEKS OF ADJUVANT CHEMOTHERAPY IN STAGE-II BREAST-CANCER. Breast Cancer Research and Treatment. 144-144. 1988
- CANCER-CHEMOTHERAPY AND THROMBOSIS. Thrombosis and Haemostasis. 114-114. 1987
- CANCER-CHEMOTHERAPY AND THROMBOSIS. Breast Cancer Research and Treatment. 122-122. 1987
- QUALITY-OF-LIFE IN BREAST-CANCER - AN INSTRUMENT FOR CLINICAL-TRIALS. Clinical and Investigative Medicine. A47-A47. 1986
- QUALITY-OF-LIFE IN STAGE-II BREAST-CANCER - AN INSTRUMENT FOR CLINICAL-TRIALS. Breast Cancer Research and Treatment. 102-102. 1986
- QUALITY OF LIFE (QL) IN STAGE-2 BREAST-CANCER - USE OF THE TIME TRADE-OFF (TTO) METHOD. Clinical and Investigative Medicine. A87-A87. 1985